Janssen bags new EU approval for Darzalex
Janssen’s Darzalex has been approved in Europe for the first-line treatment of patients with multiple myeloma.
Read More
Tag: ALCYONE
J&J’s Darzalex shows promise in newly-diagnosed multiple myeloma
Johnson & Johnson group Janssen has unveiled new data showing a 50 percent cut in the risk of disease progression or death in patients with newly diagnosed multiple myeloma given Darzalex on top of standard treatment.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
